Yes, You Can Have a Heart Attack Without Blockages
Yes, myocardial infarction can absolutely occur without obstructive coronary artery disease—this condition is called MINOCA (Myocardial Injury with Non-Obstructive Coronary Arteries), and it accounts for approximately 5-6% of all heart attacks. 1, 2
What MINOCA Actually Is
MINOCA is diagnosed when three criteria are met 2:
- True myocardial infarction criteria are present: elevated troponin (>99th percentile) plus symptoms of ischemia, new ECG changes, pathological Q waves, or imaging evidence of new myocardial damage
- Coronary angiography shows no stenosis ≥50% in any epicardial artery
- Non-ischemic mimickers are ruled out (myocarditis, Takotsubo cardiomyopathy excluded)
The 2026 Fifth Universal Definition of Myocardial Infarction has updated terminology from "myocardial infarction" to "myocardial injury" with non-obstructive coronary arteries, emphasizing that MINOCA is a working diagnosis requiring further investigation to identify the underlying cause 1.
Why This Happens: The Mechanisms
Atherosclerotic Causes (≈66% of cases) 2
- Plaque rupture or erosion with thrombus formation
- Calcific nodules causing thromboembolism
- These mechanisms are similar to typical MI but don't create ≥50% stenosis visible on angiography
Non-Atherosclerotic Causes 2
Spontaneous Coronary Artery Dissection (SCAD)
- Accounts for ~4% of all MIs overall
- 40% of MIs in women under age 50
- 14-43% of pregnancy-related MIs
- Intramural hematoma obstructs flow without atherosclerotic plaque
- May require intravascular imaging (OCT/IVUS) to diagnose if not obvious on angiography
Coronary Vasospasm
- Hyperreactivity of vascular smooth muscle (epicardial or microvascular)
- Can be provoked by drugs (cocaine, 5-fluorouracil), allergens, or occur spontaneously
- Diagnosed by provocative testing with acetylcholine or ergonovine (>90% sensitivity)
Coronary Microvascular Dysfunction (CMD)
- Impaired nitric oxide-mediated vasodilation
- Reduced myocardial blood flow reserve
- Prevalence in MINOCA uncertain but increasingly recognized
Thromboembolism
- Uncommon (<3% of cases)
- Often affects microcirculation, may not be visible on angiography
This Is NOT a Benign Condition
MINOCA carries significant mortality risk—in fact, recent data shows it may have WORSE outcomes than obstructive MI in older adults 3:
- 5-year mortality hazard ratio of 1.48 compared to revascularized ACS (adjusted HR 1.48,95% CI 1.07-2.05)
- Composite rate of death or recurrent MI is 4.6% (more than double the rate in patients without atherosclerotic disease)
- 10-year MACE rates vary by CMR findings: 3.5% if normal, 47% if acute MI pattern, 24% if myocarditis, 50% if non-ischemic cardiomyopathy 2
Critical Diagnostic Pitfall to Avoid
The most common mistake is stopping at "no blockages" and assuming the patient is fine. The 2024 Canadian Cardiovascular Society guidelines emphasize a systematic cascade 2:
- Confirm MINOCA diagnosis (MI criteria met + no stenosis ≥50%)
- Re-review angiography carefully—look for SCAD or small branch occlusions that may have been missed
- Perform cardiac MRI within 2 weeks (ideally)—identifies the final diagnosis in 85% when combined with intravascular imaging 2
- Consider intravascular imaging (OCT) if available—reveals culprit lesions in 46% of cases, plaque disruption in 43% 2
- Functional testing for vasospasm or microvascular dysfunction if other tests unrevealing
The Bottom Line for Clinical Practice
Despite optimal workup, the cause remains undiagnosed in only 8-25% of MINOCA cases 2. The 2026 guidelines now frame MINOCA as "myocardial injury" rather than "infarction" to emphasize it's a working diagnosis requiring systematic investigation 1. Most patients (22-27%) are ultimately diagnosed with true myocardial infarction after CMR, while others have myocarditis, Takotsubo syndrome, or other non-ischemic causes 1.
The key message: "No blockages" on angiography does NOT mean "no heart attack" and does NOT mean "no risk." These patients require the same aggressive secondary prevention as obstructive CAD patients, tailored to their specific underlying mechanism once identified 2, 4.